<DOC>
	<DOC>NCT02072447</DOC>
	<brief_summary>This study aims to determine the absolute bioavailability of YH4808 using simultaneous oral therapeutic- and [14C]-labeled intravenous microdoses.</brief_summary>
	<brief_title>Absolute Bioavailability of YH4808 With Accelerator Mass Spectrometry(AMS)-Based Microdose Study</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<criteria>healthy male subject aged 20 to 45 at screening subjects who have weight over 55 kg with BMI ranged from 20.0 to 25.0 subjects who decide to participate voluntarily and write a informed consent form subjects who have clinically significant disease of cardiovascular, respiratory, renal, endocrinological, hematological, gastrointestinal, neurological(central nervous system), psychiatric disorders or malignant tumor clinically significant allergic disease (except for mild allergic rhinitis) subjects who have determined not eligible by screening test (medical history, physical examination, 12lead ECG, laboratory test, etc) within 28 days of study start subjects considered unsuitable for inclusion by the investigator</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>absolute bioavailability,</keyword>
	<keyword>microdose,</keyword>
	<keyword>AMS</keyword>
</DOC>